Clinical Trial Update: Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating the combination of lenalidomide with topotecan in advanced ovarian cancer and primary peritoneal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Lenalidomide (lenalidomide)
• Topotecan (topotecan)

Snippet

Sponsor: Celgene Corporation | Conditions: Ovarian Cancer | Phase 1, Phase 2 | Status: COMPLETED